Key Points
- Claritev EVP Michael Kim bought 15,000 shares on March 12 at $16.50 each ($247,500), raising his direct holdings to 182,878 shares — an 8.94% increase; he also acquired 30,000 shares on Feb. 27 at $14.30.
- Institutional investors now own 87.15% of Claritev, with recent notable stakes and purchases by firms including Invesco, Third Point, XTX Topco and Arini Capital Management.
- Analysts are mixed (three Buys, one Hold, one Sell), giving an average rating of "Hold" and an average target price of $29.67 for the stock.
Claritev (NYSE:CTEV - Get Free Report) CFO Douglas Michael Garis purchased 1,300 shares of the company's stock in a transaction on Monday, March 16th. The stock was bought at an average price of $17.69 per share, for a total transaction of $22,997.00. Following the completion of the purchase, the chief financial officer directly owned 206,152 shares of the company's stock, valued at $3,646,828.88. The trade was a 0.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Claritev Trading Up 3.8%
Shares of NYSE:CTEV opened at $17.54 on Tuesday. The company has a market capitalization of $289.59 million, a PE ratio of -1.01 and a beta of 0.61. Claritev has a twelve month low of $12.04 and a twelve month high of $74.07. The firm has a 50 day simple moving average of $23.69 and a 200-day simple moving average of $42.54.
Institutional Trading of Claritev
A number of large investors have recently bought and sold shares of CTEV. State of Wyoming acquired a new position in Claritev in the fourth quarter valued at $25,000. Ameritas Investment Partners Inc. purchased a new position in shares of Claritev during the third quarter worth about $42,000. Legal & General Group Plc acquired a new position in Claritev in the 3rd quarter valued at about $45,000. Los Angeles Capital Management LLC purchased a new stake in Claritev during the 4th quarter valued at approximately $45,000. Finally, BNP Paribas Financial Markets acquired a new stake in Claritev during the 3rd quarter worth approximately $79,000. Institutional investors and hedge funds own 87.15% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. Guggenheim reissued a "buy" rating on shares of Claritev in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Claritev in a report on Monday, December 29th. Wells Fargo & Company set a $30.00 target price on Claritev and gave the stock an "equal weight" rating in a research report on Tuesday, February 24th. UBS Group reissued a "buy" rating on shares of Claritev in a report on Tuesday, February 24th. Finally, Citigroup decreased their target price on Claritev from $63.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday, February 25th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $29.67.
Read Our Latest Report on Claritev
Claritev Company Profile
(
Get Free Report)
Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
